Gene Polymorphism Clinical Trial
Official title:
PCSK9 Polymorphism and Risk of Mechanical Complications Following Acute Myocardial Infarction
| Verified date | October 2023 |
| Source | Maastricht University Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Protein convertase subtilisin/kexin type 9 (PCSK9) plays a regulatory role in cholesterol homeostasis by promoting low-density lipoprotein receptor (LDLr) degradation. Although the vast majority of the studies have focused on the role of PCSK9 in LDLr expression in the liver, an increasing body of evidence suggests that PCSK9 gene is also present in extra-hepatic tissues. A recent publication showed for the first time that PCSK9 is expressed in the ischemic heart and the expression is highest in the zone bordering the infarcted areas. Furthermore, the expression of PCSK9 is maximal early, at 1 week of ischemia. Mechanical complications (or cardiac ruptures) are uncommon but potentially lethal sequelae of acute myocardium infarction (AMI) and are commonly associated with early mortality without appropriate surgical intervention. It's unknown why some patients develop these devasting complications following AMI, while others not. Interestingly, studies have shown that post-infarction cardiac rupture affect the border zone between the ischemic and normal area and occur within the first 3 to 5 days after AMI. Based on the aforementioned observations, it's likely to assume a relationship between PCSK9 expression and the development of post-AMI cardiac rupture. Therefore, the main purpose of the this project is to study the PCSK9 gene polymorphism and its association with cardiac rupture. Investigators hypothesize that PCSK9 expression/secretion and development of post-AMI cardiac rupture may be a part of the dynamic changes at cellular levels occurring in the ischemic heart of genetically predisposed patients.
| Status | Recruiting |
| Enrollment | 100 |
| Est. completion date | May 31, 2024 |
| Est. primary completion date | August 31, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - clinical diagnosis of acute myocardial infarction with ST sopra-elevation (control group) - clinical diagnosis of acute myocardial infarction complicated by cardiac rupture Exclusion Criteria: - absence of coronary artery disease |
| Country | Name | City | State |
|---|---|---|---|
| Italy | Matteo Matteucci | Varese |
| Lead Sponsor | Collaborator |
|---|---|
| Maastricht University Medical Center |
Italy,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | PCSK9 gene polymorphism | PCSK9 gene polymorphism (studied at patient admission and recovery for acute myocardial infarction) | up to 1 year |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04735913 -
Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults
|
Early Phase 1 | |
| Recruiting |
NCT06431789 -
Prospective Observational Association Between SLCO1B1 Gene Polymorphism and the Anti-factor Xa Activity of Edoxaban in Patients With Moderate to Severe Renal Insufficiency
|
||
| Completed |
NCT05380128 -
Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population
|
||
| Recruiting |
NCT04960774 -
Risk Factors for Severe Periodontitis in 30 to 40 Year Olds: a Retrospective Study
|